Last reviewed · How we verify
NCT05380297
Validation of acceXible's Automated Speech Analysis Method for the Early Detection and Monitoring of Patients With Mild Impairment or Dementia in Primary Care
NA trial testing Speech analysis in Mild Cognitive Impairment in 273 participants. Completed in 18 April 2024.
18 April 2024
Quick facts
| Lead sponsor | Accexible |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 273 |
| Start date | 17 May 2021 |
| Primary completion | 18 April 2024 |
| Estimated completion | 18 April 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Speech analysis
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
- Dementia — all drugs for Dementia →
Sponsor
Accexible — full company profile →
Who can join
Adults 55 to 90, any sex, with Mild Cognitive Impairment or Dementia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dementia, especially dementia caused by Alzheimer's disease, is considered one of the most severe health problems of our time. It is currently known that the disease begins many years before clinical symptoms appear. The sooner the patient is diagnosed, the sooner the patient will be in a position to prevent further deterioration. A recent orientation is the analysis of language in relation to the description of images with a high and varied semantic and emotional content. It can be studied that changes in the description of an image check if these changes are associated with the evolution of a person with probable impairment both in memory and cognitive as well as emotional, psychiatric, behavioral and even in their interaction with environmental factors especially those associated with socialization and loneliness. Thus, the purpose of this study is to validate speech analysis AI models.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05380297
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Speech analysis
Trials testing the same drug.
- NCT05340218 — Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment · NA · completed
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other Accexible trials
Trials by the same sponsor.
- NCT06044818 — Validation of Accexible as a Tool for Screening and Monitoring Depression. · completed
- NCT05534958 — UK Validation of the Automated "AcceXible" Speech Analysis Software · completed
- NCT05340218 — Short-term Automated Longitudinal Analysis of Speech and Language in Cognitive Impairment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05380297 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Accexible
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05380297.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing